RU2214824C2 - Комбинация ингибитора обратного захвата 5-ht и антагониста или частичного агониста h5-ht1b - Google Patents

Комбинация ингибитора обратного захвата 5-ht и антагониста или частичного агониста h5-ht1b Download PDF

Info

Publication number
RU2214824C2
RU2214824C2 RU2000109563/14A RU2000109563A RU2214824C2 RU 2214824 C2 RU2214824 C2 RU 2214824C2 RU 2000109563/14 A RU2000109563/14 A RU 2000109563/14A RU 2000109563 A RU2000109563 A RU 2000109563A RU 2214824 C2 RU2214824 C2 RU 2214824C2
Authority
RU
Russia
Prior art keywords
methylpiperazin
combination
tetrahydro
naphthyl
morpholinobenzamide
Prior art date
Application number
RU2000109563/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2000109563A (ru
Inventor
Стефан БЕРГ (SE)
Стефан Берг
Сванте РОСС (SE)
Сванте Росс
Сет-Олов ТОРБЕРГ (SE)
Сет-Олов Торберг
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2000109563A publication Critical patent/RU2000109563A/ru
Application granted granted Critical
Publication of RU2214824C2 publication Critical patent/RU2214824C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Replacement Of Web Rolls (AREA)
  • Winding, Rewinding, Material Storage Devices (AREA)
RU2000109563/14A 1997-09-18 1998-09-09 Комбинация ингибитора обратного захвата 5-ht и антагониста или частичного агониста h5-ht1b RU2214824C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703375-7 1997-09-18
SE9703375A SE9703375D0 (sv) 1997-09-18 1997-09-18 A new combination

Publications (2)

Publication Number Publication Date
RU2000109563A RU2000109563A (ru) 2002-01-27
RU2214824C2 true RU2214824C2 (ru) 2003-10-27

Family

ID=20408295

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000109563/14A RU2214824C2 (ru) 1997-09-18 1998-09-09 Комбинация ингибитора обратного захвата 5-ht и антагониста или частичного агониста h5-ht1b

Country Status (29)

Country Link
US (1) US6159971A (enExample)
EP (1) EP1014985B1 (enExample)
JP (1) JP2001516718A (enExample)
KR (1) KR20010024076A (enExample)
CN (1) CN1195519C (enExample)
AR (1) AR015448A1 (enExample)
AT (1) ATE240733T1 (enExample)
AU (1) AU752722B2 (enExample)
BR (1) BR9812088A (enExample)
CA (1) CA2302382A1 (enExample)
DE (1) DE69814882T2 (enExample)
DK (1) DK1014985T3 (enExample)
EE (1) EE04141B1 (enExample)
ES (1) ES2200370T3 (enExample)
HU (1) HUP0200602A3 (enExample)
IL (1) IL134776A0 (enExample)
IS (1) IS5406A (enExample)
MY (1) MY116280A (enExample)
NO (1) NO20001399L (enExample)
NZ (1) NZ503171A (enExample)
PL (1) PL339371A1 (enExample)
PT (1) PT1014985E (enExample)
RU (1) RU2214824C2 (enExample)
SE (1) SE9703375D0 (enExample)
SK (1) SK2852000A3 (enExample)
TR (1) TR200000727T2 (enExample)
TW (1) TW589183B (enExample)
WO (1) WO1999013877A1 (enExample)
ZA (1) ZA987817B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
PL367480A1 (en) * 2001-05-01 2005-02-21 H.Lundbeck A/S The use of enantiomeric pure escitalopram
JP5080716B2 (ja) * 2001-07-20 2012-11-21 サイコジェニックス・インコーポレーテッド 注意欠陥・多動性障害の治療
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
AR047553A1 (es) 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
KR100511288B1 (ko) * 2003-11-14 2005-08-31 엘지전자 주식회사 4대의 압축기를 구비한 공기조화기의 실외기
WO2006091725A1 (en) * 2005-02-23 2006-08-31 The Silvan S. Tomkins Institute Treatment of anhedonia
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
FR2890862B1 (fr) * 2005-09-19 2008-01-25 Sanofi Aventis Sa Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
MX2009001551A (es) 2006-08-14 2009-02-20 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas.
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
MX2009002031A (es) 2006-08-25 2009-03-06 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo.
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533268A1 (en) * 1991-09-18 1993-03-24 Glaxo Group Limited Benzanilide derivatives as 5-HT1D antagonists
EP0533267A1 (en) * 1991-09-18 1993-03-24 Glaxo Group Limited Benzanilide derivatives as 5-HT1D antagonists
RU2000109558A (ru) * 1997-09-18 2002-02-10 Астразенека Аб Комбинация селективного антагониста 5-нт1a и селективного антагониста или частичного агониста н5-нт1b

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533268A1 (en) * 1991-09-18 1993-03-24 Glaxo Group Limited Benzanilide derivatives as 5-HT1D antagonists
EP0533267A1 (en) * 1991-09-18 1993-03-24 Glaxo Group Limited Benzanilide derivatives as 5-HT1D antagonists
RU2000109558A (ru) * 1997-09-18 2002-02-10 Астразенека Аб Комбинация селективного антагониста 5-нт1a и селективного антагониста или частичного агониста н5-нт1b
RU2000109560A (ru) * 1997-09-18 2002-02-10 Астразенека Аб Комбинация ингибитора моноаминоксидазы и селективного антагониста или частичного агониста н5-нт1b

Also Published As

Publication number Publication date
SK2852000A3 (en) 2000-09-12
EE200000141A (et) 2001-02-15
US6159971A (en) 2000-12-12
JP2001516718A (ja) 2001-10-02
NO20001399D0 (no) 2000-03-17
PL339371A1 (en) 2000-12-18
IS5406A (is) 2000-03-15
EE04141B1 (et) 2003-10-15
HUP0200602A2 (hu) 2002-07-29
NZ503171A (en) 2002-02-01
TW589183B (en) 2004-06-01
ZA987817B (en) 1999-03-18
CN1278729A (zh) 2001-01-03
HUP0200602A3 (en) 2003-04-28
AR015448A1 (es) 2001-05-02
WO1999013877A1 (en) 1999-03-25
AU752722B2 (en) 2002-09-26
CA2302382A1 (en) 1999-03-25
KR20010024076A (ko) 2001-03-26
ES2200370T3 (es) 2004-03-01
AU9193098A (en) 1999-04-05
HK1032739A1 (en) 2001-08-03
DE69814882D1 (de) 2003-06-26
TR200000727T2 (tr) 2000-09-21
MY116280A (en) 2003-12-31
PT1014985E (pt) 2003-10-31
ATE240733T1 (de) 2003-06-15
IL134776A0 (en) 2001-04-30
NO20001399L (no) 2000-05-10
SE9703375D0 (sv) 1997-09-18
DE69814882T2 (de) 2004-05-19
EP1014985A1 (en) 2000-07-05
EP1014985B1 (en) 2003-05-21
DK1014985T3 (da) 2003-09-15
CN1195519C (zh) 2005-04-06
BR9812088A (pt) 2000-09-26

Similar Documents

Publication Publication Date Title
RU2214824C2 (ru) Комбинация ингибитора обратного захвата 5-ht и антагониста или частичного агониста h5-ht1b
RU2000109563A (ru) Комбинация обратного поглощения 5-нт селективного антагониста или частичного агониста н5-нт1b
JP2001516718A5 (enExample)
JP2001516719A5 (enExample)
ES2246487T3 (es) Reboxetina para tratar la neuropatia periferica.
JP2008538741A (ja) 鬱病の治療用及び／又は予防用の医薬組成物
RU97119427A (ru) Сочетание ингибитора усвоения 5-нт с селективным 5-нтia антагонистом
RU2397166C2 (ru) Новые производные фталазинона в качестве ингибиторов киназы аврора-а
JP2009526821A (ja) 注意欠陥多動性障害治療用の新規な医薬組成物
AR035603A1 (es) Derivados de piperazina, composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento como agentes serotonergicos
AR013503A1 (es) Una combinacion de un inhibidor de la monoamina oxidasa y un antagonista o agonista parcial selectivo de h5-ht(1b), formulacion farmaceutica, usos ymetodo de preparacion
RU2215528C2 (ru) Комбинация селективного антагониста 5-нт1a и селективного антагониста или частичного агониста н5-нт1b
RU2007120690A (ru) Комбинации антагонистов никотинового ацетилхолинового альфа-7-рецептора
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
RU2010154417A (ru) Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств
RU2350618C2 (ru) ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
RU2000109558A (ru) Комбинация селективного антагониста 5-нт1a и селективного антагониста или частичного агониста н5-нт1b
BR0207433A (pt) Derivados de isoxazolina como antidepressivos
BR0308982A (pt) Combinações de epinastina, beladona e pseudoefedrina como novas formulações farmacêuticas
JP2001516717A5 (enExample)
RU2011131532A (ru) Способ лечения бессонницы
BRPI0415651A (pt) métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica
RU2000109560A (ru) Комбинация ингибитора моноаминоксидазы и селективного антагониста или частичного агониста н5-нт1b
RU2005135649A (ru) Комбинации пароксетина и 4-(s)-(4-ацетилпиперазин-1-ил)-2-(r)-(4-фтор-2-метилфенил)пиперидин-1-карбоновой кислоты [1-(r)-(3, 5-бис-трифторметилфенил)этил]метиламида для лечения депрессии и/или тревоги
RU2003115431A (ru) Новые применения объединенных агонистов 5-нт1а и ингибиторов обратного захвата серотонина

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20050910